Metabolic Disease Archives - Sanford Burnham Prebys
Institute News

Digestion-aiding herbs alter gut microbiome

AuthorMonica May
Date

July 24, 2019

Many medicines used today—including aspirin, penicillin and malaria-fighting quinine—originated from nature. Now, Sanford Burnham Prebys and UC San Diego scientists have turned to ancient digestive herbs to learn about gut health—in the hopes of uncovering new treatments for colon cancer, autoimmune conditions and additional serious diseases.

In a recent study published in Evidence-Based Complementary and Alternative Medicine, the researchers examined how four herbs—turmeric, ginger, long pepper and black pepper—change the gut microbiome. These herbs have been used for more than 5,000 years to aid digestion in Ayurvedic healing, India’s traditional system of medicine. The researchers found that the herbs promoted strong shifts in the gut bacteria that are known to regulate metabolism—providing insights that could help us protect our health. 

“Scientists have long known that these four herbs facilitate digestion and increase bioabsorption of dietary nutrients. However, the effects on the gut microbiome had not been studied,” says Scott Peterson, PhD, senior author of the paper and a professor at Sanford Burnham Prebys. “Our study demonstrates for the first time that these herbs indeed alter the microbiome and produce distinct shifts in microbial populations. This finding is a starting point from which we can begin to decipher how the microbiota may change the gut biochemistry to promote and protect our health.” 

Digestive disorders, including Crohn’s disease, celiac disease and irritable bowel syndrome (IBS), are increasingly prevalent in Western populations. More than 60 million people are affected in the United States alone. Treatments for the disorders are limited.

In the study, the scientists collected stool samples from 12 healthy men and women between the ages of 30 and 60 who ate a vegetarian or vegan diet. The samples were grown in medium (food for bacteria) supplemented with turmeric, ginger, black pepper or long pepper. Genomic sequencing was then used to identify how the abundance of species within the community was altered by the herbal supplement. 

The scientists found that all of the herb-supplemented samples had unique proportions of bacterial families compared to control cultures—indicating the herbs altered the gut microbiome. 

“We are exploring how different herbs produce distinct microbial signatures in the gut,” says Peterson. “It’s clear from this study that each herb works differently. Now the task is to make the connections between the herb profiles and gut health.” 

Next, the researchers plan to test the herbs’ therapeutic potential in a controlled human clinical trial. In parallel, they will work in the lab to dissect the herbs’ molecular components and study how these components influence the gut microbiome and promote digestive health.

“By delving deeper into the beneficial molecules present in these herbs and how microbes may alter those constituents, we may be able to enhance their potential benefit and help people suffering from serious digestive disorders,” explains Peterson.  


The first author of the study is Christine T. Peterson, PhD, of UC San Diego. 

Additional authors include Dmitry A. Rodionov, PhD, of Sanford Burnham Prebys and the Russian Academy of Sciences; Stanislav N. Iablokov of the Russian Academy of Sciences and Yaroslavl State University; Meredith A. Pung, PhD, and Paul J. Mills, PhD, of UC San Diego; Deepak Chopra, MD, of UC San Diego and the Chopra Foundation. Deepak Chopra is the founder of the Chopra Foundation and Chopra Center and a co-owner of the Chopra Center. Mills is the director of research for the Chopra Foundation.

The research was supported by the Samuel Lawrence Foundation, the Chopra Foundation and the Russian Science Foundation (19-14-00305).

Institute News

Leading cardiometabolic researcher to join SBP

Authordrobison
Date

November 5, 2015

The cardiovascular researcher who pioneered visualizing the function of the human heart using the most powerful magnetic resonance available will soon join SBP’s Florida campus. E. Douglas Lewandowski, PhD, will become professor in the Cardiovascular Metabolism Program and director of Cardiovascular Translational Research starting December 2015. He is among the most preeminent investigators in the world who specialize in the metabolic basis of heart failure, including ischemic heart disease and diabetic cardiomyopathy.

“Doug Lewandowski’s pioneering work has unveiled new concepts and therapeutic strategies aimed at improving the treatment of heart failure, a worldwide health problem. He will continue this work at SBP, leading an innovative bench-to-clinic research program at SBP and the Florida Hospital Translational Research Institute for Metabolism and Diabetes (TRI-MD). His recruitment is transformational for our translational research efforts in the cardiovascular arena,” said Daniel P. Kelly, MD, Tavistock Distinguished Professor and scientific director, Center for Metabolic Origins of Disease at SBP Lake Nona.

Lewandowski’s contributions to understanding metabolic pathways and fuels that may protect against the high-morbidity, -mortality, and economic health burden of heart failure are recognized as among the most rigorous and field-advancing. He is renowned in the use of nuclear magnetic resonance (NMR) spectroscopy to visualize and measure metabolic activity in the intact beating heart in health and disease. His expertise in medical imaging techniques involves manipulation of metabolic activity in the ailing heart with pharmacological agents and targeted gene manipulation.

He will hold a joint appointment at Florida Hospital as senior principal investigator at the TRI-MD. He views the partnership between SBP’s basic research and the TRI’s clinical investigations as an attractive and effective research model that will accelerate the translation of the fundamental mechanisms of heart disease and therapeutic targets toward patient-based studies to identify new treatments, therapeutics, and cures.

“With Lake Nona’s emphasis and existing expertise in cardiometabolic disease, I feel that I can immediately contribute to team science approaches to elucidate fundamental mechanisms of heart and metabolic disease. My focus will be to translate findings in SBP’s laboratories to human studies of the metabolic basis of heart disease at the TRI,” said Lewandowski. “It is this partnership that I anticipate will be a game changer in the way I will be able to implement the translation of my laboratory investigations, and I find this very, very exciting.”

Prior to joining SBP, Lewandowski held the position of professor in the Department of Physiology and Biophysics, in the Department of Medicine, and director of the Program in Integrative Cardiac Metabolism at the University of Illinois at Chicago. Previously, Dr. Lewandowski spent a decade on the faculty at Harvard Medical School with hospital appointments at Massachusetts General Hospital in Boston, Mass.

Institute News

Science on Screen: Join us in Orlando on January 24

Authorpbartosch
Date

January 9, 2015

We’re excited to announce that Sanford-Burnham’s Sheila Collins, PhD, professor in the Metabolic Disease Program, will be participating in the Enzian Theater’s “Science on Screen” event on January 24 in Orlando (Maitland), Fla. Dr. Collins will discuss her work studying metabolic disease and how far we’ve come in finding treatments for diabetes and its complications. After her 15-minute talk, the audience will watch the movie “Steel Magnolias,” featuring Julia Roberts, Sally Field, and Dolly Parton. After the movie, attendees will have the opportunity to ask questions, either related to diabetes in the movie or the topic of metabolic disease as a whole. Continue reading “Science on Screen: Join us in Orlando on January 24”

Institute News

A new link between obesity, inflammation, and insulin resistance

Authorsgammon
Date

July 17, 2014

A new study by researchers at Sanford-Burnham Medical Research Institute (Sanford-Burnham) has identified a new signal that triggers the events leading to insulin resistance in obesity. The signal causes inflammation in adipose tissue and leads to metabolic disease. The study, published July 17 in Cell Metabolism, suggests that blocking this signal may protect against the development of metabolic disease, type 2 diabetes, and other disorders caused by obesity-linked inflammation. Continue reading “A new link between obesity, inflammation, and insulin resistance”